Specifically, Semaglutide (SEMA), a glucagon-like peptide-1 receptor agonist (GLP-1 RA) molecule approved for the treatment of both type 2 diabetes (T2D) and obesity associated with significant improvement in metabolic syndrome parameters [43, 44], was tested since fasting HFD mice showed lower GLP-1 circulating levels (Suppl. The gene discussed is GCG; the disease is obesity disorder.